Academic Cancer Center Phase I Program Development.
Multiple factors critical to the effectiveness of academic phase I cancer programs were assessed among 16 academic centers in the U.S. Successful cancer centers were defined as having broad phase I and I/II clinical trial portfolios, multiple investigator-initiated studies, and correlative science. The most significant elements were institutional philanthropic support, experienced clinical research managers, robust institutional basic research, institutional administrative efforts to reduce bureaucratic regulatory delays, phase I navigators to inform patients and physicians of new studies, and a large cancer center patient base. New programs may benefit from a separate stand-alone operation, but mature phase I programs work well when many of the activities are transferred to disease-oriented teams. The metrics may be useful as a rubric for new and established academic phase I programs.The Oncologist2017;22:369-374.
University of Texas Southwestern Medical Center, Dallas, Texas, USA arthur.frankel@utsouthwestern.edu.
Arthur E
AE
Frankel
Harvard Medical School, Boston, Massachusetts, USA.
Keith T
KT
Flaherty
Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, USA.
George J
GJ
Weiner
City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Robert
R
Chen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
Nilofer S
NS
Azad
Georgetown University Medical Center, Lombardi Cancer Center, Washington DC, USA.
Michael J
MJ
Pishvaian
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, USA.
John A
JA
Thompson
Oregon Health and Science University, Portland, Oregon, USA.
Matthew H
MH
Taylor
University of Arizona Cancer Center, Tucson, Arizona, USA.
Daruka
D
Mahadevan
Alvin J. Siteman Cancer Center at the Washington University School of Medicine, St. Louis, Missouri, USA.
A Craig
AC
Lockhart
Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, USA.
Ulka N
UN
Vaishampayan
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jordan D
JD
Berlin
University of Michigan, Ann Arbor, Michigan, USA.
David C
DC
Smith
Institute for Drug Development at the Cancer Therapy and Research Center of the University of Texas Health Science Center, San Antonio, Texas, USA.
John
J
Sarantopoulos
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Matthew
M
Riese
Comprehensive Cancer Center at the University of Alabama, Birmingham, Alabama, USA.
Mansoor N
MN
Saleh
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Chul
C
Ahn
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Eugene P
EP
Frenkel
D000046:Academic Medical Centers; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology* / Q000235:genetics; D016730:Program Development; D014481:United States